Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 6:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1513–1536 of 2,414 matching trials from the live ClinicalTrials.gov search.
Conditions
MASLD, MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease), NAFLD, NAFLD (Nonalcoholic Fatty Liver Disease)
Interventions
LiverScope® exam, MR exam, Blood draw, Body measurements, Questionnaire
Diagnostic Test · Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
La Jolla, California
Completed Not applicable Interventional Accepts healthy volunteers

Glycemic Index and Brain Function

NCT01064778
Conditions
Obesity
Interventions
Low GI, High GI
Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 35 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
3
States / cities
Boston, Massachusetts
Conditions
Traumatic Head Injury, Intracranial Hemmorhage, Anti-platelet Therapy
Interventions
Saline, Platelets
Other
Lead sponsor
Christiana Care Health Services
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Newark, Delaware
Conditions
HIV Infection, Hepatitis C Infection, Fibrosis, Inflammation
Interventions
Not listed
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Chicago, Illinois
Conditions
Anal Cancer, HIV Infection, Human Papilloma Virus Infection
Interventions
comparison of screening methods, laboratory biomarker analysis, questionnaire administration, quality-of-life assessment
Procedure · Other
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years and older · Female only
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
11
States / cities
Los Angeles, California • San Francisco, California • Chicago, Illinois + 6 more
Completed No phase listed Observational Accepts healthy volunteers Results available

Opportunistic Screening for Prediabetes and Early Diabetes in Primary Care

NCT00787839
Conditions
Type 2 Diabetes Mellitus, Prediabetic State
Interventions
Glucose challenge test, Glucose tolerance test
Other
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
1,939 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Decatur, Georgia
Recruiting No phase listed Observational

Safe and Explainable AI

NCT06694181
Conditions
Artifical Inteligence, Cardiology, Breast Cancer, Sepsis
Interventions
AI-PERSONALIZED CLINICAL DECISION SUPPORT
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
300,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Limited Stage Lung Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8
Interventions
3-Dimensional Conformal Radiation Therapy, Atezolizumab, Biospecimen Collection, Carboplatin, Cisplatin, Etoposide, Intensity-Modulated Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration
Radiation · Drug · Procedure + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
544 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
532
States / cities
Birmingham, Alabama • Fairbanks, Alaska • Gilbert, Arizona + 400 more
Conditions
Acne Vulgaris
Interventions
Trifarotene 0.005 % Topical Cream, AKLIEF®, Placebo
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
12 Years to 40 Years
Enrollment
807 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
14
States / cities
West Covina, California • Brandon, Florida • Fort Lauderdale, Florida + 9 more
Conditions
Healthy
Interventions
Fosinopril sodium and hydrochlorothiazide 20-12.5 mg tablets
Drug
Lead sponsor
Ranbaxy Laboratories Limited
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Saint Charles, Missouri
Completed Not applicable Interventional Results available

Genetically Guided Statin Therapy

NCT01894230
Conditions
Hypercholesterolemia, Hydroxy-methylglutaryl-coenzyme A (HMG Co-A) Reductase Inhibitors Adverse Reaction
Interventions
SLCO1B1*5 allele testing, results reported at randomization, SLCO1B1*5 allele testing, results reported at end of study, Genetic testing for SLCO1B1*5 allele
Genetic
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
2
States / cities
Travis Air Force Base, California • Durham, North Carolina
Conditions
Cough Reflex Sensitivity
Interventions
Cosmed QuarkSpiro Dosimeter-Controlled Nebulizer, DeVilbiss 45 Handheld Nebulizer
Device
Lead sponsor
University of Montana
Other
Eligibility
18 Years to 89 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Missoula, Montana
Completed Not applicable Interventional Results available

Integration of Hypertension Management Into HIV Care in Nigeria

NCT04704336
Conditions
Human Immunodeficiency Virus, Hypertension
Interventions
Task-shifting strategy for HTN control (TASSH) protocol
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 85 Years
Enrollment
830 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Pregnancy Related
Interventions
Redraw for analysis of blood samples from healthy pregnant women
Diagnostic Test
Lead sponsor
Luna Genetics
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
157 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Houston, Texas
Conditions
Pulmonary Disease, Chronic Obstructive, Lung Diseases, Obstructive
Interventions
blood draw
Other
Lead sponsor
University of Michigan
Other
Eligibility
40 Years to 80 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus-Related Oropharyngeal Squamous Cell Carcinoma, Stage I Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage II Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Interventions
Biospecimen Collection, Cisplatin, Computed Tomography, Diffusing Alpha-emitter Radiation Therapy, Docetaxel, Intensity-Modulated Proton Therapy, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Modified Barium Swallow Study, Observation Activity, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire
Procedure · Drug · Radiation + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Completed Phase 3 Interventional Accepts healthy volunteers

Genetics Informatics Trial (GIFT) of Warfarin to Prevent DVT

NCT01006733
Conditions
Thromboembolism
Interventions
Pharmacogenetic, Target INR 1.8
Genetic · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
65 Years and older
Enrollment
1,598 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
6
States / cities
Chicago, Illinois • St Louis, Missouri • New York, New York + 2 more
Conditions
Hypertension, Cardiovascular Diseases, Cardiovascular Risk Factors, Circadian Rhythms, Sleep
Interventions
At-home Polysomnography, Circadian Protocol, Rested Wakefulness Trial, Overnight Sleep Trial, Regularized Sleep Schedule
Other · Behavioral
Lead sponsor
Oregon Health and Science University
Other
Eligibility
25 Years to 64 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Radionuclide Imaging, Sunitinib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Suspended Not applicable Interventional Accepts healthy volunteers

Real-time Neuromuscular Control of Exoskeletons

NCT04661891
Conditions
Stroke
Interventions
Isometric contractions, Isokinetic contractions, Dynamic contractions, Isometric contraction with muscle fatigue, Multi-joint functional activities while wearing exoskeleton, Clinical Assessments
Other · Device
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
18 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Classic Hodgkin Lymphoma
Interventions
Biospecimen Collection, Brentuximab Vedotin, Computed Tomography, Dacarbazine, Echocardiography Test, Gemcitabine, Pembrolizumab, Physical Performance Testing, Positron Emission Tomography, Pulmonary Function Test
Procedure · Drug · Biological + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Duarte, California
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Gojiberry Intake (Lycium Barbarium) on Macular Function

NCT03983525
Conditions
Macular Pigment Optical Density
Interventions
Goji berry, Lutein + zeaxanthin supplementation
Dietary Supplement
Lead sponsor
University of California, Davis
Other
Eligibility
45 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Davis, California
Conditions
High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified, Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
Interventions
Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Ibrutinib, Lenalidomide, Magnetic Resonance Imaging, Obinutuzumab, Positron Emission Tomography, Prednisone, Venetoclax
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
114
States / cities
Tucson, Arizona • Los Angeles, California • Derby, Connecticut + 93 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

Prospective Evaluation of Self-Testing to Increase Screening

NCT03898167
Conditions
Cervical Cancer, Human Papillomavirus Infection
Interventions
Telephone Recall, Mailed HPV Self-Sampling Kit, Patient Navigation
Behavioral
Lead sponsor
Baylor College of Medicine
Other
Eligibility
30 Years to 65 Years · Female only
Enrollment
2,474 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Houston, Texas